Psychopharmacology
October 11, 2025
Michelle St Pierre, Elena Argento, Jordyn Cates et al.
Repeated self-administration of small doses of psychedelics, known as microdosing, has been associated with perceived improvements in psychological functioning. However, few studies have examined effects at the daily level. Drawing on data from a naturalistic, prospective, international survey of adults who microdose (N = 1435), we assessed self-reported within-person changes between...
Psychopharmacology (Berl)
November 1, 2024
Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al.
9 citations
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2024
Michelle St Pierre, Lucas Standing, Yarissa Herman et al.
3 citations
A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced growing attention in the past decade and may be an increasing topic of patient-physician interactions. The stigmatization of psychedelic use may complicate this process. However, patient...
PLoS One
2024
Elena Argento, Tashia Petker, Jayesh Vig et al.
3 citations
This study explores therapists' perspectives on experiential learning, competencies, and training in ketamine-assisted therapy (KAT), a form of psychedelic-assisted therapy (PAT). We aim to understand how therapists' personal psychedelic experiences influence their self-perceived competency and therapeutic relationships regarding KAT. Licensed therapists from Numinus Wellness clinics in Canada...
Journal of Psychoactive Drugs
October 10, 2023
Ashmita Grewal, Kalysha Closson, Gina Martin et al.
11 citations
Survivors of adverse childhood experience are at elevated risk for psychological distress. In recent years, renewed interest in psychedelic medicine has highlighted the therapeutic potential of psilocybin for those who have experienced childhood adversity. However, recreational psilocybin use remains illegal and access to approved therapies is difficult. Such use provides an opportunity to...
Therapeutic Advances in Psychopharmacology
2023
Vivian W. L. Tsang, Brendan Tao, Shannon Dames et al.
19 citations
In the last few years, ketamine is becoming increasingly common in the treatment of mental health conditions, but there is a lack of safety data informing intramuscular and sublingual dosing in a community-focused group psychotherapy setting. The Roots To Thrive ketamine-assisted therapy (RTT-KaT) program is a unique 12-week RTT-KaT program with 12 community of practice (a form of group...
Sci Rep
July 28, 2022
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al.
2 citations
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
Scientific Reports
June 30, 2022
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al.
53 citations
Abstract Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further...
BJPsych Open
January 18, 2022
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al.
28 citations
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
BJPsych Open
December 23, 2021
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al.
180 citations
Background In the past two decades, subanaesthetic doses of ketamine have been demonstrated to have rapid and sustained antidepressant effects, and accumulating research has demonstrated ketamine's therapeutic effects for a range of psychiatric conditions. Aims In light of these findings surrounding ketamine's psychotherapeutic potential, we systematically review the extant evidence on...
Scientific Reports
November 18, 2021
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey et al.
78 citations
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers ( n = 4050) and non-microdosers ( n = 4653) via a mobile application. Psilocybin was the most commonly...
Frontiers in Psychiatry
September 6, 2021
Elena Argento, Devon Christie, Lindsay Mackay et al.
12 citations
The COVID-19 pandemic stands to have impacts on mental health and well-being that will extend beyond its formal resolution. Before COVID-19, mental health disorders were already challenging global healthcare systems, directly accounting for 7.4% of the total burden of disease (1, 2). An estimated 1 billion people worldwide suffer from a mental health disorder, with the two most common...
Psychopharmacology
September 1, 2019
Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al.
364 citations
Retracted
Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...
International Review of Psychiatry
July 4, 2018
Zach Walsh, Michelle S. Thiessen
65 citations
This narrative review examines evidence related to the potential for third wave behaviour therapies to serve as adjuncts to psychedelic-assisted therapy. It identifies shared theoretical foundations for both approaches, and notes enhanced mindfulness, decentering, emotion regulation, and distress tolerance as common mechanisms of action. It also identifies potential targets for which both...
Journal of Psychopharmacology
May 29, 2018
Michelle S. Thiessen, Zach Walsh, Brian M. Bird et al.
58 citations
Background: Recent evidence suggests that psychedelic use predicts reduced perpetration of intimate partner violence among men involved in the criminal justice system. However, the extent to which this association generalizes to community samples has not been examined, and potential mechanisms underlying this association have not been directly explored. Aims: The present study examined the...
Journal of Psychopharmacology
October 17, 2017
Peter S. Hendricks, Michael S Crawford, Karen L. Cropsey et al.
91 citations
Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal behavior, but the extent of these effects has not been comprehensively explored. In this study, we tested the relationships of classic psychedelic use and psilocybin use per se with criminal behavior among over 480,000 United States adult...
Journal of Psychopharmacology
April 19, 2016
Zach Walsh, Peter S. Hendricks, Stephanie D. Smith et al.
63 citations
Evidence suggests that hallucinogens may have therapeutic potential for addressing a variety of problem behaviors related to the externalizing spectrum of psychopathology, such as substance misuse and criminality. Intimate partner violence (IPV) is a prevalent form of criminal violence that is related to externalizing pathology. However, the association between hallucinogen use and IPV has not...